Karyopharm Therapeutics Inc.
KPTIKaryopharm Therapeutics Inc. (KPTI) is a pharmaceutical company focused on the development and commercialization of novel therapies for cancer and other diseases. The company is known for its pioneering work in nuclear export inhibition, particularly through its lead product, selinexor, which is used to treat multiple myeloma and certain other hematologic cancers. Karyopharm’s approach involves targeting the nuclear export pathway to reactivate tumor suppressor proteins and enhance cancer cell death.
Company News
Menarini Group and Stemline Therapeutics announced positive Phase 3 SENTRY trial results showing that selinexor combined with ruxolitinib met the primary endpoint for spleen volume reduction (SVR35) at 49.8% versus 28% for ruxolitinib alone in myelofibrosis patients. The combination also demonstrated a promising early overall survival signal with...
Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for multiple myeloma, a blood cancer affecting over 176,404 people worldwide. This year, the International Myeloma Foundation invites individuals to share their most meaningful myeloma milestones, celebrating resilience, ...
The global glioblastoma multiforme treatment market is expected to grow from $2.78 billion in 2024 to $5.68 billion by 2033, driven by advancements in immunotherapy and research for better treatment options.
Karyopharm Therapeutics (KPTI) has been beaten down lately, but the stock is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier, indicating a potential turnaround.
The advanced melanoma therapeutics market is poised for significant growth, driven by the development of innovative biologics, particularly immunotherapy medications. The pipeline report highlights 55+ active players working on 60+ pipeline therapies for advanced melanoma treatment.
